Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist - Test2 - elhamkhani - TriplyDB

Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist

Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist

http://www.wikidata.org/entity/Q26750021

about

Investigational drugs for treating major depressive disorder.Investigational drugs in recent clinical trials for treatment-resistant depression.Beyond serotonin: newer antidepressants in the future.Beyond Ketamine: New Approaches to the Development of Safer Antidepressants.

P2860

Q34547274-2652B439-DE61-472B-8CFE-F0DF330A5E00 Q34549390-68AE45E8-316D-4687-AE0E-2272E8BD2DF8 Q34557706-6FE5FD55-3145-49A6-941D-7C700A9DB132 Q47963007-AB190E87-DF13-4DA6-888E-FAC255B90557

P2860

Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist

http://www.wikidata.org/entity/Q26750021

description

2015 nî lūn-bûn

@nan

2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Preclinical pharmacology and p ...... -aspartate receptor antagonist

@ast

Preclinical pharmacology and p ...... -aspartate receptor antagonist

@en

Preclinical pharmacology and p ...... -aspartate receptor antagonist

@nl

type

label

Preclinical pharmacology and p ...... -aspartate receptor antagonist

@ast

Preclinical pharmacology and p ...... -aspartate receptor antagonist

@en

Preclinical pharmacology and p ...... -aspartate receptor antagonist

@nl

prefLabel

Preclinical pharmacology and p ...... -aspartate receptor antagonist

@ast

Preclinical pharmacology and p ...... -aspartate receptor antagonist

@en

Preclinical pharmacology and p ...... -aspartate receptor antagonist

@nl

P1433

Q26750021-4C87CD7C-3B2D-4163-95CF-A98C5C5CD6EE

P1476

Q26750021-7B51895C-829A-461C-9329-93B6D29E59E4

P2093

Q26750021-0703EBB9-5038-4FFA-83A2-A45A5D0F59B6

Q26750021-16DE177A-CE8D-4946-81BB-2D943FAAB3A4

Q26750021-2F6F9350-2CA1-4CFD-BDE1-FA36FD317957

Q26750021-3340AF76-35C6-445E-B394-D9C068957FBA

Q26750021-5A3244BF-3FFA-4385-8AFA-E990431BD7F5

Q26750021-5AFD2F37-D645-4BEC-A8ED-1C0E28D64E1C

Q26750021-739A1397-D566-402F-9038-71B248A38B17

Q26750021-796ACD7D-C850-4C25-92AD-B3D95EEB11E6

Q26750021-7BCD74A8-BE6A-406C-8D1A-64C3434E7120

Q26750021-94F1B3EF-BE4E-4D01-BEE7-CF4B4973AE92

P2860

Q26750021-06A33521-FCA6-4868-9056-367916285C41

Q26750021-0717F505-2FA0-49B0-893A-9CC9A8FD5C63

Q26750021-0F2BB013-DFD2-4C58-93EE-A5D795F52A03

Q26750021-26BD34D6-92FB-4D31-9685-67BEC416B8A7

Q26750021-292A18E3-66F1-4743-A23E-A56BDEABBEFE

Q26750021-2E683D01-0477-4CF7-A76E-2F9AA6F739C7

Q26750021-2EAB9257-FE12-4587-8788-17427331F8D3

Q26750021-31DB2B6D-DE74-4049-885C-94B5670ADACB

Q26750021-3D22524A-C099-449A-908C-8DFAA9BC7EC0

Q26750021-3FE765F9-7AAD-4F37-8A65-68142C074F58

P304

Q26750021-8708878F-0652-46EF-B653-22E3B8EF44D4

P31

Q26750021-86575C98-2A39-41C7-82C9-22791C70DC10

P356

Q26750021-749055AB-8024-4DCC-B766-125777DD0FA0

P407

Q26750021-F3156237-331A-436B-A155-2ECE175FB2A8

P433

Q26750021-B9FF65D0-D29A-4B35-BAEC-2AB1C7D8DC71

P478

Q26750021-183692C6-59F1-41DD-933E-D938419E364E

P577

Q26750021-C68DD852-9EF8-4997-A214-B282A9E6D949

P5875

Q26750021-79FB5D1D-3FFF-4FB8-BDE3-EC629DDE7FD3

P698

Q26750021-DCB06C50-CDDB-4F39-993E-4C0CB511D175

P921

Q26750021-1DE5F33B-FE79-4084-A32F-14DE40D8C7BE

Q26750021-AE62ACCE-932B-4219-AF6C-C02CFABEA3A1

P932

Q26750021-C07EE269-2470-4440-A56D-C7AB18E22ED3

P356

P1433

Pharmacology research & perspectives

P1476

Preclinical pharmacology and p ...... -aspartate receptor antagonist

@en

P2093

Armando Lagrutta

http://www.w3.org/2001/XMLSchema#string

Blake M Paterson

http://www.w3.org/2001/XMLSchema#string

Christine Fandozzi

http://www.w3.org/2001/XMLSchema#string

James J Vornov

http://www.w3.org/2001/XMLSchema#string

John A McCauley

http://www.w3.org/2001/XMLSchema#string

Joseph J Lynch

http://www.w3.org/2001/XMLSchema#string

Laszlo Kiss

http://www.w3.org/2001/XMLSchema#string

Nigel J Liverton

http://www.w3.org/2001/XMLSchema#string

Rachel Garner

http://www.w3.org/2001/XMLSchema#string

Reza Mazhari

http://www.w3.org/2001/XMLSchema#string

P2860

A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders

Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date

Crystal structure of a heterotetrameric NMDA receptor ion channel

The glutamate receptor ion channels

Antidepressant effects of ketamine in depressed patients

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

P304

e00198

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PRP2.198

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

290478190

http://www.w3.org/2001/XMLSchema#string

P698

27022470

http://www.w3.org/2001/XMLSchema#string

P921

pharmacokinetics

P932

4777252

http://www.w3.org/2001/XMLSchema#string